PortfoliosLab logoPortfoliosLab logo
CURE.DE vs. SPYH.DE
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

CURE.DE vs. SPYH.DE - Performance Comparison

The chart below illustrates the hypothetical performance of a €10,000 investment in VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and SPDR MSCI Europe Health Care UCITS ETF (SPYH.DE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CURE.DE achieves a -5.10% return, which is significantly lower than SPYH.DE's -1.97% return.


CURE.DE

1D
4.01%
1M
6.73%
YTD
-5.10%
6M
-8.62%
1Y
6.04%
3Y*
-2.48%
5Y*
10Y*

SPYH.DE

1D
3.34%
1M
0.41%
YTD
-1.97%
6M
-0.47%
1Y
6.02%
3Y*
2.85%
5Y*
5.81%
10Y*
6.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CURE.DE vs. SPYH.DE - Yearly Performance Comparison


2026 (YTD)2025202420232022
CURE.DE
VanEck Genomics and Healthcare Innovators UCITS ETF A
-5.10%5.09%0.30%-6.42%-4.35%
SPYH.DE
SPDR MSCI Europe Health Care UCITS ETF
-1.97%7.82%3.98%7.88%2.61%

Correlation

The correlation between CURE.DE and SPYH.DE is 0.50, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.50

Correlation (3Y)
Calculated over the trailing 3-year period

0.41

Correlation (All Time)
Calculated using the full available price history since Sep 8, 2022

0.42

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CURE.DE vs. SPYH.DE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CURE.DE
CURE.DE Risk / Return Rank: 1313
Overall Rank
CURE.DE Sharpe Ratio Rank: 1313
Sharpe Ratio Rank
CURE.DE Sortino Ratio Rank: 1414
Sortino Ratio Rank
CURE.DE Omega Ratio Rank: 1313
Omega Ratio Rank
CURE.DE Calmar Ratio Rank: 1313
Calmar Ratio Rank
CURE.DE Martin Ratio Rank: 1212
Martin Ratio Rank

SPYH.DE
SPYH.DE Risk / Return Rank: 1515
Overall Rank
SPYH.DE Sharpe Ratio Rank: 1515
Sharpe Ratio Rank
SPYH.DE Sortino Ratio Rank: 1515
Sortino Ratio Rank
SPYH.DE Omega Ratio Rank: 1515
Omega Ratio Rank
SPYH.DE Calmar Ratio Rank: 1515
Calmar Ratio Rank
SPYH.DE Martin Ratio Rank: 1515
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CURE.DE vs. SPYH.DE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and SPDR MSCI Europe Health Care UCITS ETF (SPYH.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CURE.DESPYH.DEDifference
Sharpe ratioReturn per unit of total volatility

-0.08

Sortino ratioReturn per unit of downside risk

-0.11

Omega ratioGain probability vs. loss probability

1.06

1.08

-0.01

Calmar ratioReturn relative to maximum drawdown

0.30

0.50

-0.20

Martin ratioReturn relative to average drawdown

0.68

1.10

-0.42

CURE.DE vs. SPYH.DE - Sharpe Ratio Comparison

The current CURE.DE Sharpe Ratio is 0.29, which is comparable to the SPYH.DE Sharpe Ratio of 0.37. The chart below compares the historical Sharpe Ratios of CURE.DE and SPYH.DE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CURE.DESPYH.DEDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.29

0.37

-0.08

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.36

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.39

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.14

0.43

-0.57

Drawdowns

CURE.DE vs. SPYH.DE - Drawdown Comparison

The maximum CURE.DE drawdown since its inception was -34.80%, which is greater than SPYH.DE's maximum drawdown of -26.62%. Use the drawdown chart below to compare losses from any high point for CURE.DE and SPYH.DE.


Loading charts...

Drawdown Indicators


CURE.DESPYH.DEDifference

Max Drawdown

Largest peak-to-trough decline

-34.80%

-26.62%

-8.18%

Max Drawdown (1Y)

Largest decline over 1 year

-19.07%

-12.58%

-6.49%

Max Drawdown (3Y)

Largest decline over 3 years

-29.32%

-26.62%

-2.70%

Max Drawdown (5Y)

Largest decline over 5 years

-26.62%

Max Drawdown (10Y)

Largest decline over 10 years

-26.62%

Current Drawdown

Current decline from peak

-15.66%

-10.72%

-4.94%

Average Drawdown

Average peak-to-trough decline

-15.12%

-8.61%

-6.51%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.53%

5.73%

+2.80%

Volatility

CURE.DE vs. SPYH.DE - Volatility Comparison

VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and SPDR MSCI Europe Health Care UCITS ETF (SPYH.DE) have volatilities of 5.73% and 6.01%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CURE.DESPYH.DEDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.73%

6.01%

-0.28%

Volatility (6M)

Calculated over the trailing 6-month period

15.20%

12.04%

+3.16%

Volatility (1Y)

Calculated over the trailing 1-year period

19.97%

17.05%

+2.92%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

20.74%

15.76%

+4.98%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

20.74%

15.82%

+4.92%

CURE.DE vs. SPYH.DE - Expense Ratio Comparison

CURE.DE has a 0.35% expense ratio, which is higher than SPYH.DE's 0.18% expense ratio.


Dividends

CURE.DE vs. SPYH.DE - Dividend Comparison

Neither CURE.DE nor SPYH.DE has paid dividends to shareholders.


Tickers have no history of dividend payments

Frequently Asked Questions


CURE.DE and SPYH.DE have a correlation of 0.50, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

On fees, SPYH.DE is cheaper at 0.18% per year. The better choice depends on whether you care most about return, fees, risk, or income.

SPYH.DE is cheaper with a 0.18% expense ratio, compared with 0.35% for CURE.DE.

CURE.DE tracks MVIS Global Future Healthcare ESG, while SPYH.DE tracks MSCI Europe Health Care 20/35 Capped. They also come from different issuers: VanEck and State Street. Their fees differ too: 0.35% for CURE.DE and 0.18% for SPYH.DE.

Portfolio Optimizer

Find the right allocation for CURE.DE and SPYH.DE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer